CytoMed Therapeutics (GDTC) Other Non-Current Liabilities (2023 - 2025)
CytoMed Therapeutics (GDTC) posted Other Non-Current Liabilities of $19338.8 for Q4 2025, down 78.09% sequentially from $88268.0 in Q2 2025, and up 115.36% YoY from $8980.0 in Q4 2024.
CytoMed Therapeutics (GDTC) Other Non-Current Liabilities (2023 - 2025) Analysis & Trends
CytoMed Therapeutics has reported Other Non-Current Liabilities for 3 years, with the latest figure at $19338.8 in Q4 2025.
- Quarterly Other Non-Current Liabilities rose 115.36% year-over-year to $19338.8 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $19338.8 (up 115.36% YoY) and the FY2025 annual result came in at $19491.0, up 117.97% from the prior year.
- Other Non-Current Liabilities slipped to $19338.8 in Q4 2025 per GDTC's latest filing, from $88268.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $108595.1 in Q4 2023 and troughed at $8980.0 in Q4 2024.
- A 3-year average of $56295.5 and a median of $53803.4 in 2025 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities sank 91.73% in 2024, then surged 115.36% in 2025.
- Over 3 years, Other Non-Current Liabilities stood at $108595.1 in 2023, then tumbled by 91.73% to $8980.0 in 2024, then surged by 115.36% to $19338.8 in 2025.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $19338.8, $88268.0, and $8980.0 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | CytoMed Therapeutics | 10.72 Mn | 9.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 19,338.83 |
| Jun 30, 2025 | 88,268.00 |
| Dec 31, 2024 | 8,979.97 |
| Dec 31, 2023 | 108,595.14 |